Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway.


PURPOSE:Our previous studies have reported the antitumor effect of oleandrin on osteosarcoma; however, its chemosensitizing effect in osteosarcoma treatment is still unknown. Therefore, we explored the sensitizing effects of oleandrin to cisplatin in osteosarcoma and investigated the potential mechanisms. METHODS:After exposure to oleandrin and/or cisplatin, CCK-8 and colony formation assays, DAPI staining and flow cytometry were performed to detect cell proliferation and apoptosis in 143B, U-2OS and MG-63 osteosarcoma cells. The median-effect analysis was applied to evaluate the combined effect. Western blot was used to determine the expression of related proteins. Osteosarcoma xenografts and histological observations were applied to confirm the combined effect in vivo. RESULTS:Compared with cisplatin or oleandrin alone, the combined treatment significantly inhibited cell proliferation and induced cell apoptosis. The median-effect analysis indicated a synergistic cytotoxic effect. The combined treatment downregulated Bcl-2 and upregulated Bax and cleaved caspase-3, -8 and -9. And the suppression of caspases reduced cell death. Furthermore, oleandrin alone or with cisplatin, activated the p38 MAPK/Elk-1 pathway. The inhibition of the p38 MAPK pathway increased cell viability and reduced apoptosis. In vivo, the combined treatment was also verified to significantly inhibit tumor growth, induce apoptosis and activate the p38 MAPK pathway. CONCLUSIONS:The combination of oleandrin with cisplatin exerts a synergistic antitumor effect in osteosarcoma, which relates to the activation of the p38 MAPK pathway.


Yong L,Ma Y,Zhu B,Liu X,Wang P,Liang C,He G,Zhao Z,Liu Z,Liu X




Has Abstract


2018-12-01 00:00:00














  • Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.

    abstract:PURPOSE:To characterize cobimetinib pharmacokinetics and evaluate impact of clinically relevant covariates on cobimetinib pharmacokinetics. METHODS:Plasma samples (N = 4886) were collected from 487 patients with various solid tumors (mainly melanoma) in three clinical studies (MEK4592g, NO25395, GO28141). Cobimetinib ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Han K,Jin JY,Marchand M,Eppler S,Choong N,Hack SP,Tikoo N,Bruno R,Dresser M,Musib L,Budha NR

    更新日期:2015-11-01 00:00:00

  • An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.

    abstract::Trastuzumab has deeply and radically changed the course of HER2-positive breast cancer disease. The recent development of a subcutaneous (SC) formulation of trastuzumab is an important step towards improved patients' care. SC trastuzumab at a fixed dose of 600 mg administered every 3 weeks for about 5 min provides a v...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Launay-Vacher V

    更新日期:2013-12-01 00:00:00

  • Effect of cortisol on cell proliferation and the expression of lipoprotein lipase and vascular endothelial growth factor in a human osteosarcoma cell line.

    abstract:PURPOSE:The aim of this study is to investigate whether cortisol inhibited cell proliferation and the expressions of lipoprotein lipase (LPL), a key enzyme involved in the energy metabolism in tumor cells, and vascular endothelial growth factor (VEGF), a potent angiogenic factor in the tumor, in cultures of OST cells, ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Sakayama K,Mashima N,Kidani T,Miyazaki T,Yamamoto H,Masuno H

    更新日期:2008-03-01 00:00:00

  • Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells.

    abstract:BACKGROUND AND PURPOSE:Human type I fatty acid synthase has been proposed as a chemotherapeutic target for the treatment of breast cancer based on the inactivation of human beta-ketoacyl synthase activity by cerulenin. Triclosan, a common antibiotic, functions by inhibiting the enoyl-reductase enzymes of type II fatty ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Liu B,Wang Y,Fillgrove KL,Anderson VE

    更新日期:2002-03-01 00:00:00

  • The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen.

    abstract:PURPOSE:We have developed and evaluated a CNS-targeted chemotherapy regimen based on the pharmacokinetic properties of the individual drugs in the combination. PATIENTS AND METHODS:In a twin-track study, 16 patients with secondary CNS lymphoma (SCNSL) and 8 with primary CNS lymphoma (PCNSL) were treated with IDARAM wh...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,多中心研究


    authors: Moreton P,Morgan GJ,Gilson D,Smith GM,McVerry BA,Davies JM,Mackie MJ,Bolam S,Jalihal SS,Howard MR,Parapia LA,Williams AT,Child JA,Central and Southern Lymphoma Group.

    更新日期:2004-04-01 00:00:00

  • Antitumor activity of treosulfan in human lung carcinomas.

    abstract::Treosulfan (L-threitol 1,4-bismethanesulfonate, Ovastat) is an alkylating agent and a structural analogue of busulfan. It has been established in the clinical chemotherapy of human ovarian carcinomas for several years and has additionally been shown to be effective against xenografted human breast carcinomas. No other...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Köpf-Maier P,Sass G

    更新日期:1996-01-01 00:00:00

  • Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.

    abstract::The discovery of targetable mutations, which cause gene rearrangement, led to a major advancement in the treatment of patients with non-small cell lung cancer (NSCLC), and cancers with such mutations can be paired with drugs which specifically target them. c-ros oncogene (ROS1) positive NSCLC is one molecular subtype ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审


    authors: Roys A,Chang X,Liu Y,Xu X,Wu Y,Zuo D

    更新日期:2019-10-01 00:00:00

  • Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer.

    abstract:PURPOSE:O(6)-benzylguanine (BG) is a pseudosubstrate inactivator of the DNA repair protein O(6)- alkylguanine-DNA alkyltransferase (AGT) that has entered clinical trials as a potentiator of the antitumor effect of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). This study was designed to evaluate potential mechanisms of B...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Phillips WP Jr,Gerson SL

    更新日期:1999-01-01 00:00:00

  • Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.

    abstract:PURPOSE:Thymidylate synthase (TS) is one of the target molecules for the antitumor effects of fluoropyrimidine drugs. The cellular thymidylate synthase level is one of the determining factors for the antitumor activity of fluoropyrimidines. TYMS, which encodes TS, has been reported to possess 28-bp tandem repeat sequen...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Yawata A,Kim SR,Miyajima A,Kubo T,Ishida S,Saito Y,Nakajima Y,Katori N,Matsumoto Y,Fukuoka M,Ohno Y,Ozawa S,Sawada J

    更新日期:2005-11-01 00:00:00

  • Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study.

    abstract::Between April 1986 and May 1989 a multicentre study was conducted to evaluate the efficacy of a 4-h intravenous infusion of 1000 mg/m2 5-fluorouracil (5-FU) followed by a 1-h infusion of 25 mg/m2 cisplatin (CDDP) given for 4 consecutive days every 4 weeks to patients with advanced squamous-cell carcinoma of the head a...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,多中心研究


    authors: Jassem J,Gyergyay F,Kerpel-Fronius S,Nagykálnai T,Baumöhl J,Verweij J,Vuletic L,Mechl Z,Drozd-Lula M,Jelic S

    更新日期:1993-01-01 00:00:00

  • Salivary passage of 5-fluorouracil during continuous infusion.

    abstract::Plasmatic and salivary concentrations of 5-FU were investigated in ten patients given 5-day continuous infusions of 5-fluorouracil (5-FU) (1 g/m2/day). Measurable concentrations of salivary 5-FU were scattered ranging from 6 to 100 ng/ml. Between individual 5-FU concentrations in saliva and plasma the coefficient of c...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Milano G,Thyss A,Santini J,Frenay M,Francois E,Schneider M,Demard F

    更新日期:1989-01-01 00:00:00

  • Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies.

    abstract:PURPOSE:The diatomic radical nitric oxide (NO) has been the cause of intense debate with implication in carcinogenesis, tumour progression, invasion, angiogenesis and modulation of therapeutic responses. The tumour biology of NO is highly complex, and this review summarises the various protective and damaging mode of a...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审


    authors: Singh S,Gupta AK

    更新日期:2011-06-01 00:00:00

  • Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer.

    abstract:PURPOSE:To compare the response rates, toxicities and survival durations of elderly patients (70 years of age or more) with those of younger patients (less than 70 years of age) with non-small-cell lung cancer (NSCLC) treated with cisplatin-based chemotherapy. PATIENTS AND METHODS:We analyzed retrospectively the data ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Kubota K,Furuse K,Kawahara M,Kodama N,Ogawara M,Takada M,Masuda N,Negoro S,Matsui K,Takifuji N,Kudoh S,Kusunoki Y,Fukuoka M

    更新日期:1997-01-01 00:00:00

  • Disulfiram: a novel repurposed drug for cancer therapy.

    abstract::Cancer is a major health issue worldwide and the global burden of cancer is expected to reduce the costs of treatment as well as prolong the survival time. One of the promising approaches is drug repurposing, because it reduces costs and shortens the production cycle of research and development. Disulfiram (DSF), whic...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审


    authors: Lu C,Li X,Ren Y,Zhang X

    更新日期:2021-01-10 00:00:00

  • Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.

    abstract:PURPOSE:Docetaxel, capecitabine, and cisplatin are effective chemotherapeutic agents for breast cancer with significant synergistic cytotoxicity demonstrated by in vitro studies. The purpose of this study was to assess the efficacy of a combination of docetaxel, capecitabine, and cisplatin (TXP) in patients diagnosed w...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究


    authors: Lu YS,Chen DR,Tseng LM,Yeh DC,Chen ST,Hsieh CM,Wang HC,Yeh HT,Kuo SH,Huang CS

    更新日期:2011-06-01 00:00:00

  • Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.

    abstract:PURPOSE:The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer. METHODS:A total...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Pilancı KN,Saglam S,Okyar A,Yucel S,Pala-Kara Z,Ordu C,Namal E,Ciftci R,Iner-Koksal U,Kaytan-Saglam E

    更新日期:2016-07-01 00:00:00

  • Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity.

    abstract::D-3-Azido-3-deoxy-myo-inositol (3AMI) is an inhibitor of the growth of v-sis-transformed NIH 3T3 cells but not of wild-type NIH 3T3 cells, whose effects may be mediated through the phosphatidylinositol-3'-kinase pathway. We studied some properties of the cellular pharmacology of 3AMI using high-specific-activity [3H]-...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Brunn G,Fauq AH,Chow S,Kozikowski AP,Gallegos A,Powis G

    更新日期:1994-01-01 00:00:00

  • Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.

    abstract:PURPOSE:The plasma and cerebrospinal fluid (CSF) pharmacokinetics of the camptothecin analogs, 9-aminocamptothecin (9-AC) and irinotecan, were studied in a nonhuman primate model to determine their CSF penetration. METHODS:9-AC, 0.2 mg/kg (4 mg/m2) or 0.5 mg/kg (10 mg/m2), was infused intravenously over 15 min and iri...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Blaney SM,Takimoto C,Murry DJ,Kuttesch N,McCully C,Cole DE,Godwin K,Balis FM

    更新日期:1998-01-01 00:00:00

  • Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates.

    abstract:PURPOSE:ABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS tumors. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of ABT-888 in a non-human primate (NHP) model that is highly predictive of human CSF penetration. METHODS:ABT-8...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Muscal JA,Thompson PA,Giranda VL,Dayton BD,Bauch J,Horton T,McGuffey L,Nuchtern JG,Dauser RC,Gibson BW,Blaney SM,Su JM

    更新日期:2010-02-01 00:00:00

  • Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.

    abstract:PURPOSE:The aims of this dose-escalating phase I study were to determine the maximum tolerable dose (MTD) and recommended dose (RD) of 5-fluorouracil (5-FU), docetaxel, and nedaplatin (UDON) combination therapy for future phase II studies, and to evaluate the safety and efficacy of this regimen in patients with untreat...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Ueda S,Kawakami H,Nishina S,Sakiyama T,Nonagase Y,Okabe T,Tamura T,Nakagawa K

    更新日期:2015-08-01 00:00:00

  • A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.

    abstract:PURPOSE:Recently, it was shown that chrysin causes upregulation of UGT1A1 in Caco-2 intestinal cells. Therefore, we proposed that oral chrysin may reduce irinotecan (CPT-11) induced diarrhoea by shifting the SN-38G/SN-38 equilibrium towards the inactive SN-38G in the gastrointestinal mucosa. The purpose of this study w...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章


    authors: Tobin PJ,Beale P,Noney L,Liddell S,Rivory LP,Clarke S

    更新日期:2006-02-01 00:00:00

  • Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.

    abstract::In five cancer patients we have determined the pharmacokinetics of 4'-deoxydoxorubicin (4'-DOX), its alcoholic metabolite 4'-deoxydoxorubicinol and the occurrence of circulating 7-deoxyaglycone metabolites. The 7-deoxyaglycone of the alcohol metabolite, the major aglycone of Adriamycin (ADR) present in man, was not de...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Cummings J,Kerr DJ,Kaye SB

    更新日期:1987-01-01 00:00:00

  • Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.

    abstract:PURPOSE:Hypoxic tumor cells overexpressing hypoxia-inducible factor 1alpha (HIF-1alpha) are generally resistant to chemo/radiotherapy. We have reported that Se-methylselenocysteine (MSC) therapeutically enhances the efficacy and selectivity of irinotecan against human tumor xenografts. The aim of this study was to deli...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Chintala S,Tóth K,Cao S,Durrani FA,Vaughan MM,Jensen RL,Rustum YM

    更新日期:2010-10-01 00:00:00

  • Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine.

    abstract::Studies are described in which a new folate analogue, edatrexate (EDX), in combination with the vinca alkaloids, vinblastine (VBL), navelbine (NVB) or vindesine (DVA) was evaluated against E0771 mammary adenocarcinoma, T241 fibrosarcoma and the Lewis lung tumor. Each of the four agents when given individually to anima...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Otter GM,Sirotnak FM

    更新日期:1994-01-01 00:00:00

  • Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases.

    abstract::In the original article, corresponding author's given name and family name are flipped. It should be "Siqing Fu" rather than "Fu Siqing". ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 已发布勘误


    authors: Fu S,Culotta KS,Falchook GS,Hong DS,Myers AL,Zhang YP,Naing A,Janku F,Hou MM,Kurzrock R

    更新日期:2016-04-01 00:00:00

  • Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. I. In vitro cytotoxicity.

    abstract::A new synthetic tripeptide (p-F-Phe-m-bis-(2-chloroethyl)amino-Phe-Met ethoxy HCl), PTT.119, was demonstrated to have significant cancericidal activity against seven in vitro tumor cell lines of different origins and etiologies and against primary human AMML, ALL, and hairy cell leukemias. Viabilities of each murine t...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Yagi MJ,Bekesi JG,Daniel MD,Holland JF,De Barbieri A

    更新日期:1984-01-01 00:00:00

  • Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.

    abstract::Mercaptopurine (6MP) has been the standard drug for maintenance therapy of acute lymphoblastic leukemia. In a multicenter study we investigated whether thioguanine (6TG), which is converted more directly to the cytotoxic thioguanine nucleotides (TGN), offers a therapeutic advantage over 6MP. In this study (COALL-92), ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验


    authors: Erb N,Harms DO,Janka-Schaub G

    更新日期:1998-01-01 00:00:00

  • Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck.

    abstract::Paclitaxel is used as a single agent, and in combination with other drugs, as a standard of care in the treatment of squamous cell carcinoma of the head and neck (SCCHN). However, the use of paclitaxel for therapy of SCCHN may be accompanied by serious side effects. Paclitaxel is a known cytotoxic inhibitor of cell pr...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Jaglowski JR,Zagon IS,Stack BC Jr,Verderame MF,Leure-duPree AE,Manning JD,McLaughlin PJ

    更新日期:2005-07-01 00:00:00

  • Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.

    abstract:PURPOSE:There is considerable current interest in the use of thalidomide as a single agent or in combination with drugs such as cyclophosphamide in the treatment of multiple myeloma and other cancers. Our previous work has shown that thalidomide potentiates the antitumour activity of both cyclophosphamide and 5,6-dimet...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Chung F,Wang LC,Kestell P,Baguley BC,Ching LM

    更新日期:2004-05-01 00:00:00

  • Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis.

    abstract:PURPOSE:High-dose methotrexate (HD-MTX) is widely used in the treatment of non-Hodgkin lymphoma (NHL), but the pharmacokinetic properties of HD-MTX in Chinese adult patients with NHL have not yet been established through an approach that integrates genetic covariates. The purposes of this study were to identify both ph...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Yang L,Wu H,de Winter BCM,Sheng CC,Qiu HQ,Cheng Y,Chen J,Zhao QL,Huang J,Jiao Z,Xie RX

    更新日期:2020-05-01 00:00:00